Background: The majority of renal cell carcinoma (RCC) studies analyze primary tumors, and the corresponding results are extrapolated to metastatic RCC tumors. However, it is unknown if gene expression profiles from primary RCC tumors differs from patient-matched metastatic tumors. Thus, we sought to identify differentially expressed genes between patient-matched primary and metastatic RCC tumors in order to understand the molecular mechanisms underlying the development of RCC metastases.
Introduction
Complete surgical excision, in the form of either partial or radical nephrectomy, for localized renal cell carcinoma (RCC) offers an opportunity for cure in RCC patients. Even with strict adherence to the 2014 National Comprehensive Cancer Network or American Urological Association surveillance guidelines, onethird of RCC recurrences will be missed [1] . Metastases of RCC tumors have been reported to virtually all organs; however, the most common sites are pulmonary and bone [2] . The location and number of metastases are highly variable and impact prognosis and response to therapy.
Although treatment options for metastatic RCC have increased over the past decade, mortality rates and 5-year survival are unacceptably poor [3, 4] . Thus, there is a clear clinical need to develop novel management and treatment strategies for metastatic RCC that will lower mortality rates and extend survival [5] . Owing to tissue availability, genome-wide interrogation of biomarkers associated with metastatic progression and cancerspecific death has primarily been based on observations made in the primary tumor [6] [7] [8] and not in the more lethal, and more therapeutically relevant metastatic lesion. And, genome-wide studies that have preliminarily interrogated metastatic specimens have done so using small sample sizes [9, 10] . Thus, the molecular mechanisms that lead to RCC metastases remain largely unknown and require further study.
To address these gaps in the knowledge, we identified genes that support RCC metastases by comparing gene expression profiles between metastatic tumors and their patient-matched primary tumor. We primarily focused on ccRCC, which accounts for more than 85% of RCC. Particularly, we employed a twostage design where we first utilized gene expression microarray technology to identify candidate genes that are associated with RCC metastases, and subsequently, validated the candidate genes in a large cohort of patient-matched primary and metastatic ccRCC tumors using a custom NanoString assay.
Methods

Patient selection
Discovery cohort. We identified 15 patients at Mayo Clinic Rochester who were treated surgically for RCC (14 ccRCC, 1 papillary), underwent metastasectomy for a pulmonary metastatic lesion, and had fresh-frozen tissue available from their primary tumor in addition to their pulmonary metastasis. One of the 15 patients had two separate pulmonary metastases; both were included in the study. A single pathologist (J.C.C.) carried out a blinded comprehensive review of all tumors (primary and metastatic) to confirm histological subtype (1997 AJCC/UICC classification), tumor stage, 2012 International Society of Urological Pathology (ISUP) tumor grade, tumor size, and coagulative tumor necrosis.
Validation cohort. We identified 114 additional patients at Mayo Clinic Rochester who were treated surgically for ccRCC between 1990 and 2005, had synchronous or metachronous metastases, and underwent metastasectomy for at least one of their metastatic lesions and therefore had formalin-fixed, paraffin-embedded tissue available from their primary tumor and at least one patient-matched metastatic tumor. Unilateral multifocal disease and bilateral disease were not considered metastatic ccRCC. A single pathologist (J.C.C.) carried out a blinded comprehensive review of all tumors (primary and metastatic) to confirm histological subtype (1997 AJCC/UICC classification), tumor stage, 2012 ISUP tumor grade, tumor size, and coagulative tumor necrosis. A representative paraffin-embedded tissue block with the highest grade and presence of necrosis was chosen from each resected tumor. If serial metastatic tumors were available, then all available metastatic tumors were analyzed in order to evaluate inter-tumor heterogeneity across serial metastatic tumors. Metastases were classified as synchronous if the metastatic tumor was resected at the same time as nephrectomy (<30 days) or metachronous if the diagnosis and resection of metastases occurred after (>30 days) nephrectomy. This study was approved by the Mayo Clinic IRB.
Affymetrix gene expression microarrays (discovery stage)
Laser capture microdissection of tumor cells was carried out and samples were hybridized to the Affymetrix U133 Plus2 microarray chip, a genome-wide gene expression assay. Microarray analysis was conducted according to the manufacturer's instructions for the Affymetrix One Cycle Target Labeling and Control Reagents kit (Santa Clara, CA). Briefly, cDNA was generated from 5 mg of total RNA using SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA) and T7 Oligo(dT) primer. Subsequently, the products were column-purified (Affymetrix) and then in vitro transcribed to generate biotin-labeled cRNA. The transcribed products were then column-purified, fragmented, and hybridized on to Affymetrix U133 Plus 2.0 GeneChips V R at 45 C for 16 h. After hybridization, the arrays were washed and stained with streptavidin-phycoerythrin, then scanned in an Affymetrix GeneChip V R Scanner 3000 (Santa Clara, CA). The data have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE85258.
NanoString (validation stage)
Total RNA was isolated from three slides per tumor at 10-mm sections of tumorrich areas of FFPE tissue blocks using the AllPrep DNA/RNA FFPE kit reagents (Qiagen) following vendor's standard protocols. Isolated FFPE RNAwas treated with 20 units DNase I. The NanoString platform was used to quantify gene expression of seven candidate genes: DCN, SLIT2, LUM, LAMA2, ADAMTS12, CEACAM6, and LMO3. Two hundred nanograms of each total RNA sample was prepared as per the manufacturer's instructions. Gene expression was quantified on the NanoString nCounter TM and raw counts were generated with nSolver TM . Raw counts per gene were extracted using the nSolver software (NanoString).
Statistical methods
Affymetrix gene expression microarray data (discovery stage).
Data were normalized using fastlo [11] . The primary objective was to identify genes that were differentially expressed between patient-matched primary and metastatic tumors. Differential expression was tested using a linear mixed-effect model; models were fit per probe set using a random effect for patient to account for the paired data. Probe sets with P-value (P) <0.00002 and a fold change > 2 were considered candidate differentially expressed genes. We were particularly interested in genes that were up regulated in metastatic tumors as these genes have the largest potential to be therapeutically targetable.
NanoString data (validation stage). Bland-Altman plots were used to visualize agreement of gene expression between primary-metastatic tumor pairs as well as between serial metastatic tumors from the same individual. Linear mixedeffect models were used to determine whether each of the seven genes was differentially expressed between the patient-matched primary and metastatic tumors; models were fit per gene using a random effect for patient to account for the paired data. Linear mixed-effects models were also used to determine whether the difference in gene expression between primary-metastatic tumor pairs was associated with metastatic site, metastatic timing (M0/M1), metastatic tumor grade, metastatic tumor necrosis (yes/no), and metastatic tumor sarcomatoid status (yes/no). To account for multiple testing, P < 0.01 was used for statistical testing.
TCGA ccRCC data
Level 3 RSEM normalized RNASeqV2 files were downloaded on 8 January 2013, from TCGA Data Portal for 428 ccRCC subjects. Cox proportional hazards regression was used to evaluate the association of each gene with metastasis-free survival and overall survival, adjusting for age at diagnosis and tumor stage. Gene expression was modeled as a continuous variable and a linear relationship was verified. Multivariable Cox regression was used to evaluate independent gene predictors of outcome. To account for testing associations of seven genes, P < 0.01 was used.
Results
Discovery stage: differential gene expression profiling of patient-matched primary and metastatic RCC tumors
The discovery cohort consisted of 15 patients that developed pulmonary metastatic tumors: 6 had a synchronous (M1) metastasis at the time of diagnosis and 9 had a metachronous (M0) metastasis (Table 1) . The majority of patients were male (87%) with Fuhrman grade 3 primary RCC tumors (60%). Affymetrix gene expression profiling identified 38 probesets that were more than twofold upregulated in metastatic tumors relative to patient-matched primary RCC tumors (P < 2 Â 10
; supplementary Table S1 , available at Annals of Oncology online). Many of these probesets mapped to genes that were associated with lung surfactants and thus were excluded from further consideration, as were probesets that mapped to open reading frames. The remaining probesets were observed to be enriched for extracellular matrix (ECM) genes. Thus, we chose to validate differential expression of the seven ECM genes that had probesets that met our significance criteria: DCN, SLIT2, LUM, LAMA2, ADAMTS12, CEACAM6, and LMO3 (Table 2) . Notably, 1 of the 15 patients in the discovery cohort had a papillary primary RCC tumor whereas the remaining 14 patients had a clear cell primary RCC tumor. Thus, as a sensitivity analysis, we analyzed only the 14 ccRCC patients. As shown in supplementary  Table S2 , available at Annals of Oncology online, the seven candidate ECM genes remain highly significant.
Validation stage: independent validation of differentially expressed ECM genes
Of the 114 patients identified, 97 (85%) had a primary tumor or a metastatic tumor that was successfully profiled by NanoString (Figure 1 ; Table 1 ); 88 patients had a primary tumor (43 synchronous and 45 metachronous) successfully profiled and 87 patients had a metastatic tumor that was successfully profiled. A total of 118 metastases were available from the 87 patients who had at least one metastatic tumor successfully profiled (Table 3) ; 59 patients had NanoString data for only a single distant metastasis and 28 patients had NanoString data on two or more metastases. The median time from nephrectomy to the first metachronous metastasis was 1.85 years (37 days, maximum 10.82 years). Metastases to pulmonary (37%) were the most common (Table 3 ). Comparing patient-matched primary and metastatic tumor pathologic characteristics, 59% had concordant grade, 60% had concordant necrosis status, and 87% had concordant sarcomatoid dedifferentiation status (supplementary Table S3 , available at Annals of Oncology online).
In the validation cohort, DCN, SLIT2, LUM, LAMA2, ADAMTS12, and LMO3 were all significantly upregulated in metastatic tumors relative to patient-matched primary ccRCC tumors (P < 0.005; Table 2 ; supplementary Figure S1 , available at Annals of Oncology online). Supplementary Table S4, available at Annals of Oncology online shows the results for testing whether differential expression was associated with metastatic site. There was a significant association between differential expression of LMO3 (P ¼ 0.0001) and CEACAM6 (P ¼ 0.0001) with metastatic site. Specifically, pulmonary metastases had larger differences of LMO3 gene expression between primary and metastatic tumors than metastases to bone, brain, liver, skin, and nodes (P < 0.01). Similarly, pulmonary metastases had larger differences of CEACAM6 gene expression than metastases to most other sites (P < 0.01). In fact, CEACAM6 was primarily expressed in pulmonary metastases (supplementary Figure S1 , available at Annals of Oncology online). Synchronous (M1) metastases had larger differences of DCN gene expression between primary and patientmatched metastatic ccRCC tumors in comparison to metachronous (M0) metastases (P < 0.01; supplementary Table S4 , available at Annals of Oncology online). Non-necrotic metastases had larger differences of SLIT2 gene expression between primary and patient-matched metastatic ccRCC tumors in comparison to necrotic metastases (P < 0.01; supplementary Table S4 , available at Annals of Oncology online). We did not observe a significant association between metastatic tumor sarcomatoid differentiation and difference in gene expression in any of the seven genes (P > 0.01; supplementary Association of ECM genes with survival in TCGA primary ccRCC tumors
After adjusting for age at diagnosis, CEACAM6 and LUM were significantly associated with metastasis-free and overall survival (P < 0.01; Table 4 ). When including both CEACAM and LUM in a multivariable Cox model (supplementary Table S5 , available at Annals of Oncology online), only LUM remained significantly (P < 0.05) associated with overall survival whereas both LUM and CEACAM6 were significantly associated with metastasis-free survival (P < 0.05). After adjustment for both ages at diagnosis and tumor stage (supplementary Table S6 , available at Annals of Oncology online); none of the seven genes were significantly associated with either overall survival or metastasis-free survival (P > 0.01).
Discussion
Although treatment options for metastatic RCC have increased over the past decade, mortality and 5-year survival remain unacceptably poor [3, 4] . TCGA identified somatic mutations, cytogenetic and epigenetic alterations in primary ccRCC tumors [8] ; however, less is known regarding common molecular alterations in the more lethal and therapeutically relevant distant metastatic tumor. In fact, it has been suggested in other cancers that the primary tumor may not be representative of the metastatic tumor and more effective molecular targets could be discovered by interrogating the metastatic tumor [12, 13] . Thus, studies that interrogate metastatic tumors directly are critical to understanding the biology of metastases, the major cause of patient mortality. We evaluated gene expression profiles using the largest set, to our knowledge, of patient-matched primary and metastatic ccRCC tumors and identified up regulation of seven ECM genes: DCN, SLIT2, LUM, LAMA2, ADAMTS12, CEACAM6, and LMO3. We utilized a two-stage design where we first identified the seven candidate ECM genes using a whole-genome screen, and subsequently, validated the upregulation of these seven genes in a large independent validation cohort that included a range of metastatic sites. We additionally observed that two of these genes (CEACAM6 and LUM) were significantly associated with metastatic-free and overall survival in primary ccRCC tumors.
The ECM pathway has been suggested to have a significant role in tumor progression and a therapeutic target in cancer [14] . However, the mechanism associated with the role of ECM with tumor progression differs across tumor sites and remains unknown for kidney cancer. Specifically, although known to be a tumor suppressor, DCN has been shown to be up regulated in oral cancer [15] and has been reported to be associated with poor outcome in RCC [16] . LUM encodes a member of the small leucine-rich proteoglycan family that includes DCN and also has been shown to be associated with poor prognosis in RCC [16] as well as in other cancers [17] . ADAMTS12 has been shown to be associated with outcome in colorectal cancer [18] ; however, to our knowledge this is the first time that ADAMTS12 has been linked to RCC. SLIT2 and LMO3 have been reported to be hypermethylated in pulmonary tumors (another smoking-related cancer) relative to patient-matched normal pulmonary tissue [19] and LMO3 has been shown to have oncogenic potential in neuroblastoma [20] . The SLIT/ROBO pathway is reported to be a therapeutic target for cancer [21] . And, although SLIT2 has been shown to be methylated in $25% of primary RCC tumors [22] , its expression in metastatic RCC has not been systematically studied. However, SLIT2 has been shown to be associated with metastases in other cancers [23, 24] . CEACAM6 is an oncogene that has been found to be associated with tumor progression and metastasis in pancreatic, breast, colon, lung, and gastric cancer [25, 26] and to be associated with poor outcome in RCC [16] . Similar to our observations in ccRCC, CEACAM6 has been shown to be upregulated in colon metastasis in comparison to primary tumors [25] . Overall, these genes represent possible targets for metastatic ccRCC and deserve further attention.
Although we observed that seven ECM genes were upregulated in RCC metastases, currently no drugs exist to specifically target these seven genes. However, other ECM components (e.g. integrins, heparanases, and matrix metalloproteinases) have inhibitors that are currently under study in phase I/II/III clinical trials [27] [28] [29] [30] [31] [32] [33] . Kinase genes have also recently been reported to be upregulated in metastatic tumors relative to primary ccRCC tumors [34] . Thus, further study is required to determine whether ECM or kinase genes represent therapeutic targets in metastatic RCC.
There are some noteworthy limitations to our study. Primary and metastatic tumors were microdissected in the discovery cohort (analyzed fresh frozen tissue) but not the validation cohort (analyzed FFPE tissue). The process of microdissection minimizes stromal contamination; however, it may also decrease the ability to detect large global changes in gene expression in the tumor microenvironment. We acknowledge that intra-tumor and microenvironment heterogeneity can impact RNA profiles; thus, a single pathologist centrally reviewed all primary and metastatic tumors blinded to the patient identifiers and selected a representative tissue block (highest grade and presence of necrosis) for analysis. Although the discovery cohort consisted solely of pulmonary metastases, we validated that the seven candidate genes were up regulated across metastatic locations in an independent validation cohort, suggesting that the presence of adjacent stroma from the affected site did not significantly influence gene expression. We also acknowledge that there are biological differences between subjects with distant metastases who undergo metastasectomy and subjects ineligible for metastasectomy. Patients with high-volume disease, rapid progression or poor performance status are less likely to undergo metastasectomy [35, 36] . Conversely, the presence of pancreatic metastases in RCC is associated with a more indolent clinical course [37] . Thus, our cohort of patient-matched primary and metastatic tumors may not be representative of all subjects with metastatic disease. It is also important to note that the metastases were treated with metastasectomy rather than systemic therapy with the exception of one patient. Lastly, our study is hypothesis generating and thus requires further functional validation to demonstrate that therapeutic targeting of ECM genes inhibits tumor growth and improves clinical outcomes. In summary, the results described herein provide important molecular evidence that metastatic ccRCC tumors are different than primary tumors and thus the metastatic tumor should be interrogated to define the key mechanisms underlying the development of metastatic disease. Specifically, our study indicates that ECM genes are upregulated in metastases in comparison to patient-matched primary RCC tumors and thus potentially offer insight into novel therapeutic targets. Overall, these ECM genes may be part of an ECM 'remodeling' program to facilitate metastatic colonization. Future preclinical studies are warranted to selectively therapeutically target upregulated ECM genes in metastases while maintaining proper ECM integrity in normal tissue.
